DAXOR CORP (10-Q) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011. Daxor Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and related diagnostic kits, alongside a cryobanking subsidiary. The company maintains a significant investment portfolio, primarily in electric utility stocks, to offset operating losses. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $377,469 | $396,272 |
| Gross Profit | $212,015 | $204,495 |
| Operating Loss | $(2,175,937) | $(1,342,156) |
| Net Loss | $(1,326,262) | $(92,419) |
| Net Loss Per Share (Basic/Diluted) | $(0.31) | $(0.02) |
| Cash and Cash Equivalents | $71,414 | $73,898 |
| Total Assets | $92,666,632 | $86,997,985 |
| Total Liabilities | $46,569,969 | $44,200,371 |
| Stockholders' Equity | $46,096,663 | $46,995,044 |
Investment Portfolio: Available-for-sale securities totaled $53,188,438 with a net unrealized gain of $23,564,789. The portfolio generated $573,666 in dividend income and $3,744,373 in realized gains, partially offset by a $4,468,429 mark-to-market loss on short positions.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 5.0% to $377,469, driven by a 5.7% drop in Volumex kit sales (809 kits sold vs. 858 in Q1 2010). No BVA-100 analyzers were sold in either period.
- Operating Expense Surge: Total operating expenses increased 54.4% to $2,387,952. This was primarily due to $870,909 in legal expenses incurred for an ongoing SEC administrative proceeding.
- Investment Volatility: While realized gains on securities dropped from $6.08M to $3.74M, the mark-to-market loss on short positions decreased slightly from $4.77M to $4.47M. The net result was a shift from investment income of $1.83M in 2010 to an investment loss of $182,784 in 2011.
- Cash Flow: Net cash used in operating activities increased to $3.86M (from $1.90M), largely due to the operating loss and a $2.21M decrease in income taxes payable.
Outlook, Risks, and Contingencies
- SEC Administrative Proceeding: The SEC is claiming Daxor is an unregistered investment company rather than an operating company. An administrative hearing occurred in March 2011. If found to be an investment company, Daxor may need to register as a Regulated Investment Company (RIC), requiring the distribution of 90% of taxable income to shareholders, or face taxation as a regular corporation.
- Key Person Risk: The company is heavily dependent on Dr. Joseph Feldschuh (CEO/President), who makes all investment decisions and is the primary scientist. The filing notes that if he were unable to continue, the company's investment returns would likely drop significantly, potentially insufficient to cover operating losses.
- Reimbursement Risk: CMS policy changes have eliminated separate Medicare reimbursement for Daxor's Volumex radiopharmaceuticals for outpatient services, requiring hospitals to absorb the cost. The impact of the Affordable Care Act remains unquantified.
- Dividend Declaration: The Board declared a dividend of $0.15 per share on May 11, 2011, payable June 16, 2011.
Investor Verification Checklist
- SEC Proceeding Status: Verify the outcome of the administrative hearing regarding the company's classification as an investment company and potential RIC status.
- Legal Expense Trajectory: Confirm if the $870,909 in Q1 legal fees represents a one-time cost or if additional expenses are expected for the remainder of the year.
- Investment Portfolio Management: Assess the risk associated with the sole reliance on Dr. Feldschuh for investment decisions and the lack of a formal succession plan for portfolio management.
- Customer Concentration: Note that four hospitals accounted for 57.89% of Blood Volume Kit sales; verify the stability of these key accounts.
- Liquidity Position: Monitor cash burn rates given the operating loss of $2.18M and the reliance on margin loans (totaling $4.95M) to fund operations and investments.